This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change GILDNegative Net Change
biotechs pharmaceuticals
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
SRPTNegative Net Change ARWRPositive Net Change ACADNegative Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
by Kinjel Shah
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
BMYPositive Net Change JNJPositive Net Change ABBVPositive Net Change BNTXPositive Net Change
pharmaceuticals
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
by Kinjel Shah
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
pharmaceuticals
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
by Sundeep Ganoria
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
by Zacks Equity Research
GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.
GSKNegative Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zacks Investment Ideas feature highlights: CVS Health, Johnson & Johnson and Tenet Healthcare
by Zacks Equity Research
CVS, JNJ, and Tenet Healthcare shine as defensive picks with strong earnings momentum and attractive valuations.
JNJPositive Net Change THCPositive Net Change CVSPositive Net Change
pharmaceuticals
3 Medical Stocks to Consider as Markets Take a Breather
by Shaun Pruitt
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
JNJPositive Net Change THCPositive Net Change CVSPositive Net Change
dividend-investing dividends earnings hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
by Zacks Equity Research
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
by Zacks Equity Research
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
REGNNegative Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
ZTSNegative Net Change EXASPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
by Zacks Equity Research
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
REGNNegative Net Change SNYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Jobs Shrink in the Summer of '25, Pre-Markets Lower
by Mark Vickery
+73K new jobs were filled last month, lower than the +100K expected. The Unemployment Rate ticked up 10 bps.
REGNNegative Net Change CVXPositive Net Change XOMPositive Net Change CLPositive Net Change
earnings interest-rate oil-energy pharmaceuticals staffing
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
by Kinjel Shah
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
AZNPositive Net Change JNJPositive Net Change
pharmaceuticals
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
by Kinjel Shah
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change BNTXPositive Net Change
pharmaceuticals
Stock Market News for Aug 1, 2025
by Zacks Equity Research
Wall Street closed lower on Thursday, pulled down by health care and real estate stocks.
MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
by Nalak Das
Boost your portfolio with ADBE, DIS, INTU, ROL and JNJ as these five wide moat stocks poised for growth and strong returns.
JNJPositive Net Change DISNegative Net Change ADBENegative Net Change INTUNegative Net Change ROLPositive Net Change
business-services computers consumer-discretionary pharmaceuticals
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
by Ahan Chakraborty
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BCRXNegative Net Change IONSPositive Net Change NTLAPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
JNJPositive Net Change TEVAPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
by Zacks Equity Research
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
by Zacks Equity Research
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
BMYPositive Net Change PFEPositive Net Change EXELNegative Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
DRRXPositive Net Change CRMDNegative Net Change BHCPositive Net Change ARVNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
by Zacks Equity Research
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
REGNNegative Net Change SNYPositive Net Change AZNPositive Net Change
pharmaceuticals
Company News for Jul 31, 2025
by Zacks Equity Research
Companies in The News Are: MO, AEP, GSK, EA
GSKNegative Net Change AEPNegative Net Change MONegative Net Change EANegative Net Change
pharmaceuticals utilities
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
by Zacks Equity Research
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
AZNPositive Net Change NVSPositive Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs earnings medical pharmaceuticals